Cortex Plans To Move CX717 Ahead In Other Indications Despite FDA Rejection For ADHD Study
This article was originally published in The Pink Sheet Daily
Agency denies Cortex investigational new drug application for a Phase IIb study of Ampakine compound CX717 in ADHD.
You may also be interested in...
Announcement comes after FDA approves a study protocol with higher doses of the Ampakine compound.
The company will not pursue an ADHD indication until further toxicological data show an increased safety margin for higher doses.
The firm will submit additional preclinical data in September on the ADHD therapy CX717.